EFFECT OF DAPAGLIFLOZIN ON HEPATIC STEATOSIS AND FIBROSIS IN TYPE 2 DIABETES MELITUS WITH NON- ALCOHOLIC FATTY LIVER DISEASE
Authors: Sharma Meenu , Kapoor Dhiraj , Manju Manju , Singh Gopal , Sharma Piyush 
Published: August 2024

Introduction: Diabetes mellitus (DM) is probably one of the oldest diseases known to man. It was rst reported in Egyptian manuscript about 3000
years ago.1 In 1936, the distinction between type 1 and type 2 DM was clearly made.2 Type 1diabetes is an autoimmune reaction that attacks cells in
your pancreas that produce insulin and is caused by inherited genetics or environmental elements. Type 2 diabetes happens when your body
becomes resistant to insulin and is associated with genetics and lifestyle changes. Diabetes is fast gaining the status of a potential epidemic in India,
with 69.2 million people living with diabetes (8.7%). Of these, more than 36 million people remained undiagnosed.3 It is predicted that by 2030
diabetes mellitus may afict up to 79.4 million individuals in India.4,5 The current scenario of diabetes in India is likely to worsen in the coming
decade. The greatest numbers of people with diabetes are between 40 and 59 years of age.6 Nonalcoholic fatty liver disease (NAFLD) is the most
common chronic liver disease, with a global prevalence of 20%-40%. Approximately 40%-60% of patients with type 2 diabetes mellitus (DM2)
experience NAFLD; out of which 20%-40% cases may have higher severity. Due to the scarcity of available reports from the eastern part of India,
we aimed to evaluate the effects of dapagliozin. Material and Method: - This was hospital-based study, randomized, active –controlled, open
label study, Place of study was Departments of Medicine, and Gastroenterology and Hepatology, Dr. Rajendra Prasad Government Medical
College, and Hospital, Kangra at Tanda. This was hospital-based study, randomized, active –controlled, open label study, Place of study was
Departments of Medicine, and Gastroenterology and Hepatology, Dr. Rajendra Prasad Government Medical College, and Hospital, Kangra at
Tanda. The study included consecutive patients with DM2 and NAFLD, treated with dapagliozin at 10 mg daily for six months. All patients
underwent detailed anthropometric, biochemical, abdominal ultrasonography, and transient elastography studies at baseline and after therapy as
well as a comparative analysis. Results:- In the 100 patients included in our study, the male and female patients (male-to- female ratio, 1:1.17).
There was no signicant difference in gender based distribution. The mean age at presentation was 55.86 ± 9.52 years. The mean body mass index
signicantly decreased over the course of the therapy, from at baseline 26.21 ± 1.51 kg/m2 to 24.02± 4.03 kg/m2 after the therapy. The patients'
transaminitis, dyslipidemia, and glycemic status signicantly improved over the course of the therapy. We also observed signicant (p < 0.05)
improvement in hepatic steatosis by the end of the treatment. Although transient elastography by Fibro Scan-measured hepatic brosis score
(Echosens, Paris, France) signicantly decreased from 9.81 ± 1.23 to 6.1 ± 1.07 kpa, hepatic brosis did improve signicantly (p ≥ 0.05) following
therapy. Conclusion:- Although dapagliozin improved body mass index, transaminitis, dyslipidemia, glycemic status, and hepatic steatosis, it
had also shown effect on hepatic brosis.